AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Biofrontera Inc.

$1.36 +$0.64 (+87.59%)
NASDAQ · 14 Sep 2026 20:00 UTC
Previous Close
$1.55
Day Range
$1.35$1.57
Year Range
$0.56$1.66
Market Cap
17.41M
AVG Volume
423.62K
Trailing/Forward PE
-2.27/6.8
PEG ratio
0.01
Dividend Yield
-
Next Earnings Date
2026-11-11
Primary Exchange
NASDAQUS
Revenue (USD)
020M40M60M202020212022202320242025
BFRI Revenue (USD) by year
PeriodRevenue (USD)
202541.71M
202437.31M
202334.07M
202228.67M
202124.1M
202018.85M
Net Income (USD)
-40M-30M-20M-10M0202020212022202320242025
BFRI Net Income (USD) by year
PeriodNet Income (USD)
2025-10.54M
2024-17.76M
2023-20.13M
2022-640K
2021-37.71M
2020-10.99M
Operating Income (USD)
-30M-20M-10M0202020212022202320242025
BFRI Operating Income (USD) by year
PeriodOperating Income (USD)
2025-9.15M
2024-17.21M
2023-22.68M
2022-18.58M
2021-25.2M
2020-8.79M
EBITDA (USD)
-40M-30M-20M-10M010M202020212022202320242025
BFRI EBITDA (USD) by year
PeriodEBITDA (USD)
2025-9.18M
2024-14.48M
2023-18.45M
2022933K
2021-36.76M
2020-7.47M
Cash Flows (USD)
-30M-20M-10M0202020212022202320242025
BFRI Cash Flows (USD) by year
PeriodCash Flows (USD)
2025-13.36M
2024-10.33M
2023-24.9M
2022-16.24M
2021-26.73M
2020-12.37M
EPS (USD)
-100-75-50-25025202020212022202320242025
BFRI EPS (USD) by year
PeriodEPS (USD)
2025-1.47
2024-4.1
2023-15.82
20229.65
2021-83.91
2020-18.7
Expenses (USD)
020M40M60MR&DSG&ACapex202020212022202320242025
BFRI Expenses (USD) by year
PeriodExpenses (USD)
202541.95M
202435.99M
202339.2M
202235.91M
202137.21M
202017.83M
Cash & Debt (USD)
010M20M30MCashLong Term DebtShort Term Debt202020212022202320242025
BFRI Cash & Debt (USD) by year
PeriodCash & Debt (USD)
20256.4M
20245.91M
20231.42M
202227.76M
202124.55M
20208.08M
Debt ratios
-0.08-0.06-0.04-0.0200.02202320242025
BFRI Debt ratios by year
PeriodDebt ratios
20250.01
20240.01
2023-0.06
Margins
0%20%40%60%80%202020212022202320242025
BFRI Margins by year
PeriodMargins
202578.66%
202450.59%
202348.8%
202247.04%
202147.13%
202050.41%
Return on Capital
-600%-400%-200%0%202020212022202320242025
BFRI Return on Capital by year
PeriodReturn on Capital
2025-100.53%
2024-400.61%
2023-420.01%
2022-2.68%
2021-332.62%
2020-188.52%
Shares Outstanding
05M10M15M202020212022202320242025
BFRI Shares Outstanding by year
PeriodShares Outstanding
202511.65M
20245.52M
20232.14M
20221.33M
2021560.04K
2020400K
Book Value Per Share (USD)
0102030202020212022202320242025
BFRI Book Value Per Share (USD) by year
PeriodBook Value Per Share (USD)
20250.9
20240.8
20232.24
202217.89
202120.24
202014.57
Total Assets (USD)
020M40M60M202020212022202320242025
BFRI Total Assets (USD) by year
PeriodTotal Assets (USD)
202528.56M
202422.1M
202327.93M
202250.88M
202153.22M
202024.14M
Employee Count
025507510020212022202320242025
BFRI Employee Count by year
PeriodEmployee Count
202572
202492
202383
202281
202169
Free Cash Flow Yield
-500%-400%-300%-200%-100%0%med -136.31%Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
BFRI Free Cash Flow Yield by year
PeriodFree Cash Flow Yield
Sep 26-45.12%
Sep 26-39.59%
Sep 26-38.11%
Aug 26-38.59%
Aug 26-41.46%
Aug 26-47.2%
Aug 26-62.8%
Jul 26-68.17%
Jul 26-73.17%
Jul 26-73.17%
Jul 26-72.5%
Jul 26-78.97%
Jun 26-82.14%
Jun 26-80.81%
Jun 26-92.19%
Jun 26-85.3%
May 26-90.02%
May 26-98.79%
May 26-99.69%
May 26-99.76%
May 26-106.22%
Apr 26-106.22%
Apr 26-104.29%
Apr 26-111.38%
Apr 26-117.07%
Mar 26-140.07%
Mar 26-131.86%
Mar 26-128.11%
Mar 26-129.69%
Feb 26-122.21%
Feb 26-125.78%
Feb 26-143.07%
Feb 26-135.7%
Jan 26-119.75%
Jan 26-111.41%
Jan 26-133.81%
Jan 26-135.12%
Jan 26-153.66%
Dec 25-154.47%
Dec 25-145.44%
Dec 25-137.15%
Dec 25-133.33%
Nov 25-136.38%
Nov 25-150.59%
Nov 25-136.24%
Nov 25-92.99%
Oct 25-91.3%
Oct 25-91.3%
Oct 25-104.62%
Oct 25-104.62%
Oct 25-93.86%
Sep 25-104.63%
Sep 25-111.59%
Sep 25-119.39%
Sep 25-118.95%
Aug 25-113.34%
Aug 25-104.22%
Aug 25-107.99%
Aug 25-211.98%
Aug 25-192.92%
Jul 25-189.28%
Jul 25-227.43%
Jul 25-233.3%
Jul 25-286.63%
Jun 25-333.51%
Jun 25-327.84%
Jun 25-304.46%
Jun 25-334.4%
May 25-357.01%
May 25-313.6%
May 25-308.82%
May 25-269.48%
May 25-260.09%
Apr 25-231.33%
Apr 25-220.31%
Apr 25-222.93%
Apr 25-253.06%
Mar 25-230.33%
Mar 25-217.75%
Mar 25-339.98%
Mar 25-342.03%
Feb 25-322.64%
Feb 25-283.49%
Feb 25-266.67%
Feb 25-273.63%
Jan 25-278.47%
Jan 25-288.69%
Jan 25-286.06%
Jan 25-280.95%
Jan 25-280.95%
Dec 24-283.49%
Dec 24-321.58%
Dec 24-296.86%
Dec 24-314.67%
Nov 24-349.63%
Nov 24-361.69%
Nov 24-428.71%
Nov 24-435.11%
Nov 24-341.74%
Oct 24-410.42%
Price to Sales
00.10.20.30.40.5med 0.22Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
BFRI Price to Sales by year
PeriodPrice to Sales
Sep 260.38
Sep 260.43
Sep 260.45
Aug 260.45
Aug 260.41
Aug 260.36
Aug 260.34
Jul 260.32
Jul 260.29
Jul 260.29
Jul 260.3
Jul 260.27
Jun 260.26
Jun 260.27
Jun 260.23
Jun 260.25
May 260.24
May 260.22
May 260.22
May 260.32
May 260.3
Apr 260.3
Apr 260.31
Apr 260.29
Apr 260.27
Mar 260.23
Mar 260.24
Mar 260.25
Mar 260.25
Feb 260.26
Feb 260.26
Feb 260.23
Feb 260.24
Jan 260.27
Jan 260.29
Jan 260.24
Jan 260.24
Jan 260.21
Dec 250.21
Dec 250.22
Dec 250.24
Dec 250.24
Nov 250.24
Nov 250.21
Nov 250.24
Nov 250.26
Oct 250.26
Oct 250.26
Oct 250.23
Oct 250.23
Oct 250.26
Sep 250.23
Sep 250.21
Sep 250.2
Sep 250.2
Aug 250.21
Aug 250.23
Aug 250.22
Aug 250.14
Aug 250.15
Jul 250.15
Jul 250.13
Jul 250.12
Jul 250.1
Jun 250.09
Jun 250.09
Jun 250.1
Jun 250.09
May 250.08
May 250.09
May 250.09
May 250.1
May 250.11
Apr 250.12
Apr 250.13
Apr 250.12
Apr 250.11
Mar 250.12
Mar 250.13
Mar 250.15
Mar 250.15
Feb 250.16
Feb 250.18
Feb 250.19
Feb 250.19
Jan 250.18
Jan 250.18
Jan 250.18
Jan 250.18
Jan 250.18
Dec 240.18
Dec 240.16
Dec 240.17
Dec 240.16
Nov 240.15
Nov 240.14
Nov 240.12
Nov 240.12
Nov 240.16
Oct 240.13
EV/EBITDA
-11.5-11-10.5-10-9.5med -10.99Mar 23Apr 23Apr 23May 23
BFRI EV/EBITDA by year
PeriodEV/EBITDA
May 23-11.19
Apr 23-11.42
Apr 23-10.42
Apr 23-11.28
Apr 23-11.14
Mar 23-10.85
Mar 23-10.56
Mar 23-9.71
Price to Book
051015med 1.17Feb 24Sep 24Dec 24Apr 25Jul 25Jun 26Sep 26
BFRI Price to Book by year
PeriodPrice to Book
Sep 262.95
Sep 263.36
Sep 263.49
Aug 263.45
Aug 263.21
Aug 262.82
Aug 262.44
Jul 262.25
Jul 262.1
Jul 262.1
Jul 262.12
Jul 261.94
Jun 261.87
Jun 261.9
Jun 261.67
Jun 261.8
May 261.71
May 261.55
May 261.54
May 261.28
May 261.2
Apr 261.2
Apr 261.22
Apr 261.14
Apr 261.09
Mar 260.91
Mar 260.97
Aug 2511.13
Aug 2512.23
Jul 2512.47
Jul 2510.38
Jul 2510.12
Jul 258.23
Jun 257.08
Jun 257.2
Jun 257.75
Jun 257.06
May 256.61
May 257.53
May 257.64
May 250.86
May 250.9
Apr 251.01
Apr 251.06
Apr 251.05
Apr 250.92
Mar 251.01
Mar 251.07
Mar 250.97
Mar 250.96
Feb 251.02
Feb 251.16
Feb 251.23
Feb 251.2
Jan 251.18
Jan 251.14
Jan 251.15
Jan 251.17
Jan 251.17
Dec 241.16
Dec 241.02
Dec 241.11
Dec 241.04
Nov 240.94
Nov 240.91
Nov 240.77
Nov 240.4
Nov 240.51
Oct 240.42
Oct 240.39
Oct 240.37
Oct 240.45
Sep 240.6
Sep 240.6
Sep 240.6
Sep 240.52
Aug 240.51
Aug 240.55
Aug 240.63
May 240.56
May 240.77
Apr 240.71
Apr 240.75
Apr 240.93
Apr 240.81
Mar 240.69
Mar 240.54
Mar 240.69
Mar 241.61
Mar 241.17
Feb 241.21
Feb 240.99
Feb 240.96
Feb 241.21
Jan 241.99
Jan 242.16
Jan 242.91
Jan 243.71
Dec 233.65
Dec 233.9
Biofrontera Inc.
BFRI
Stockpicker

Video analysis: BFRI

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: BFRI

Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma

globenewswire.com · 14 Sep 2026

Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma

Ameluz used in conjunction with the RhodoLED lamp becomes the first and only photodynamic therapy approved in the United States to treat a skin cancer, creating an additional growth opportunity for Biofrontera's photodynamic therapy platform

Biofrontera Inc. (BFRI) Q2 2026 Earnings Call Transcript

seekingalpha.com · 13 Aug 2026

Biofrontera Inc. (BFRI) Q2 2026 Earnings Call Transcript

Biofrontera Inc. (BFRI) Q2 2026 Earnings Call Transcript

Biofrontera Inc. (BFRI) Reports Q2 Loss, Beats Revenue Estimates

zacks.com · 13 Aug 2026

Biofrontera Inc. (BFRI) Reports Q2 Loss, Beats Revenue Estimates

Biofrontera Inc. (BFRI) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.57 per share a year ago.

Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth

globenewswire.com · 13 Aug 2026

Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth

WOBURN, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the quarter ended June 30, 2026.

Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026

globenewswire.com · 5 Aug 2026

Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026

WOBURN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a U.S. specialty dermatology company commercializing Ameluz® (aminolevulinic acid hydrochloride) Gel, 10% with the BF-RhodoLED® lamp for photodynamic therapy (PDT) of actinic keratosis, today announced that it will report financial results for the second quarter ended June 30, 2026 before the market opens on Thursday, August 13, 2026.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.